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Abstract Reconﬁguration of the healthcare division of labour is becoming increasingly
attractive in the context of increased patient demand and resource constraints. One
example is the introduction of extended roles for pharmacists to provide patients
additional support to manage their medicines, while also reducing work pressures
experienced by other health professionals. Understanding how such policies are
framed by those delivering and receiving care has been under-theorised. Using
Goffman’s frame theory, we examine one newly introduced community pharmacy
service (New Medicines Service (NMS)) to illustrate how a policy intended to
support patient medicine-taking through the extended roles of pharmacists is
framed and where this deviates from its proposed aims. Three themes emerged: (i)
the spatial-material artefacts; (ii) existing discursive culture and practice around
medicine-taking; and (iii) the NMS interactions that shape and govern framing and
subsequent interpretation of the NMS. Our study offers an explanatory and
dynamic view of the framing process with important lessons for reconﬁguring
medicine management policy and practice. As well as illustrating framing as being
variegated, complementary or conﬂicting, it also shows how this plurality and
fragility had consequences for patient engagement and sense-making. The
consequences for engagement and recommendations for implementing future
initiatives are discussed.
Keywords: Goffman, frame analysis, New Medicine Service (NMS), community pharmacy,
patient, General practitioner
Introduction
The appropriate, effective and safe use of medicines has become global health policy priority,
especially in the context of mounting concerns about anti-microbial resistance, the problems of
polypharmacy for long-term conditions, and the spiralling costs associated with providing
medicines in high to middle-income countries (Abbing 2016). Despite medicines prescribing
being the most common patient-level healthcare intervention, patient adherence to medicines
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prescribed for long-term conditions is variable (i.e. where patients take their medications as
directed by their healthcare professional (Vrijens et al. 2012). It is estimated that approxi-
mately 50% of prescribed medicines are not taken as directed (Brown and Bussell 2011,
Sabate 2003), and non-adherence is linked to substantial worsening of disease, increased rates
of hospitalisation and waste of scarce resource (Osterberg and Blaschke 2005). In light of the
growing problem of adherence, the ‘social life’ of medicines and how they are perceived is of
growing sociological interest. Attempts to understand medicines adherence has moved away
from the traditional conceptualisation of adherence as a simple action of taking a medicine,
towards a complex set of beliefs, attitudes and behaviours that can be affected by a range of
inﬂuences including family and social context in which medicines are taken, and interaction
with healthcare providers (Lutfey 2005, McCoy 2009, Whyte, Van der Geest and Hardon
2002).
Policymakers increasingly see the pharmacy profession, alongside other healthcare profes-
sionals, as especially well-placed to address this problem in the primary care setting, because
community pharmacists are often more accessible than other professionals due to their
extended opening hours and locations in the community (Todd et al. 2014). Government poli-
cies often see extended use of the pharmacy workforce as a means to reduce pressures on
more expensive secondary or family practice services (Imison et al. 2014). The extended role
of pharmacists in supporting medicines adherence also aligns with the contemporary ‘profes-
sionalisation project’ of moving pharmacy responsibilities away from retail and dispensing
towards patient-centred services such as advice-giving and medicines optimisation (Mossialos
et al. 2015). As a result, community pharmacy medicine management interventions are being
introduced globally including Australia (Home Medication Review (HMR) (Pharmaceutical
Society of Australia 2011), Canada (MedsCheck) (Ontario Ministry of Health and Long-Term
Care 2011), New Zealand (Medicine Use Review) (Lee et al. 2009), Switzerland (Polymedica-
tion-Checks) (Niquille et al. 2010), the United States (Medication Therapy Management)
(American Pharmacists Association and National Association of Chain Drug Stores Foundation
2008) and England (Medicine Use Review, New Medicine Service) (Pharmaceutical Services
Negotiating Committee (PSNC) 2011).
The value and acceptance of community pharmacy interventions to the public is not always
clear and pharmacists may underestimate the willingness of the public to take part in such ser-
vices (Rodgers et al. 2016, Salter 2010). Although service users typically welcome pharma-
cists’ advice when in line with expected core responsibilities (i.e. dispensing prescriptions/
advice and treatment of minor ailments), advice is less readily accepted if extended beyond
their perceived professional boundaries (Eades et al. 2011). Adoption of such services is also
hindered by lack of patient awareness, insufﬁcient integration into existing healthcare path-
ways, poor awareness among GPs (general practitioners), and pharmacist workplace barriers
(Bradley et al. 2008). In addition, because community pharmacies in the UK are independent
businesses, commercial incentives have inﬂuenced the way new services are introduced. This
commercial-professional tension has been described as ‘role strain’ or ‘role ambiguity’ (Hard-
ing and Taylor 1997, Hibbert et al. 2002). A recent example of how organisational pressures
impact on professional work can be seen in the ‘target driven’ delivery of the English MUR
service (Bradley et al. 2008). Research also suggests policy-driven service innovations and
workforce change can contribute to inter-professional competition, particularly where new roles
extend the actual or perceived jurisdiction of pharmacy at the expense of other professionals,
or for the beneﬁt of corporate interests (McDonald et al. 2010).
Recent research suggests extended roles for pharmacists can transform the relationships, not
only between health professionals, but also between professionals and patients (Edmunds and
Calnan 2001; Harding and Taylor 1997). For example, advice-giving roles have been
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interpreted as forms of ‘pastoral’ care with patients engaged in confessional and self-regulatory
behaviour (Waring et al. 2016). However, the changing social relationship between patients
and pharmacists in the context of these new services remains under-theorised. This paper
examines the implementation of a new community pharmacy medicine management service
called the ‘New Medicine Service’ (NMS), which aims to address the problems of non-adherence
for people starting a new medicine for asthma/chronic obstructive pulmonary disease (COPD),
type 2 diabetes, hypertension or antiplatelet/anticoagulant treatment (PSNC 2011). Using
Goffman’s framing perspective, we focus on the micro-realities in which this new policy is
interpreted and cascaded by health professionals through their subsequent relational interactions.
We focus in particular on pharmacists’ interactions with patients and how this shapes and
co-creates new sense-making that is context speciﬁc and situated according to circumstance.
Framing not only demonstrates the dynamic nature of health policy implementation, but
importantly the consequences of reconﬁguring the division of labour, in particular, how framing
by providers and service users is context-speciﬁc and inﬂuences outcomes.
The application of frame theory
According to frame theory, interacting individuals within in a given situation classify their experi-
ences according to guiding ‘frames of reference’ that shape how they give meaning to the situa-
tion and their interactive roles within it. Goffman deﬁnes a ‘frame’ in the following way:
I assume that deﬁnitions of a situation are built up in accordance with principles of organi-
sation which govern events – at least social ones – and our subjective involvement in them;
frame is the word I use to refer to such of these basic elements as I am able to identify.
That is my deﬁnition of frame. (Goffman 1974:10–11)
Frames enable individuals to organise and give meaning to their experiences through, for
example, ﬁltering and selecting relevant cues and providing a ‘framework’ for cognition, inter-
pretation and to guide future action. Frames are the background meanings, cognitive structures
and cultural frames of reference through which experiences are organised. It is argued that
individuals organise the frames they create according to common understanding, and so
enabling individuals, groups and society to function (Swingewood 2000). For Goffman, the
core question to be asked when analysing such frames is to determine ‘what is it that’s going
on here?’ (Goffman 1974: 9). Far from being static, an individual’s frame activity is embedded
in their ongoing reality, in what Goffman calls ‘organisational premises’:
Organisational premises . . . are something cognition somehow arrives at, not something cog-
nition creates or generates. Given their understanding of what it is that is going on, individ-
uals ﬁt their actions to this understanding and ordinarily ﬁnd that the ongoing world
supports this ﬁtting. These organizational premises – sustained in both the mind and in
activity – I call the frame of activity. (Goffman 1974: 247)
Framing has been used to explain how individuals condense manifold meanings to reduce
the complexity of the world and so enabling them to interpret and make sense of what is hap-
pening (Moscovici 1984). In these cases, frames act as a ﬁlter so that people are only receptive
to information that ﬁts to the frame. An individuals’ ‘primary framework’ helps render an
otherwise meaningless aspect of a scene into something meaningful as it is experienced (Goff-
man, 1974). As well as creating social order, frames can be fragile, multifarious, malleable,
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layered and often multidimensional (Manning 1992). The framing process is active and inﬂu-
enced by discursive and strategic processes (Benford and Snow 2000). This ﬂexibility and
multiplicity opens up possibilities for re-framing, frame misalignment and frame transforma-
tion. Goffman calls one kind of transformation ‘keying’ or staging, where new values, new
meanings and understandings are transposed onto another framework. To illustrate this, he
suggests a ‘strip of activity’ can be keyed by acts of framing, scripting, staging, and perform-
ing. However, keyed frames are likely to collapse when based on ambiguity, for instance when
an actor is unsure of which frame to apply. One example Goffman provides to illustrate this is
if someone suspects a bank is being robbed, but then only to realise that this was part of a
ﬁlming of a bank robbery. A second type of frame transformation is where frames are manu-
factured or ‘fabricated’ intentionally by one or more individuals in an effort to ‘manage activ-
ity so that a party of one or more others will be induced to have a false belief about what it is
that is going on’ (Goffman 1974: 83). These frames are liable to collapse when the deceiver is
uncovered (e.g. someone realises they have been conned) leaving the actor disoriented and
questioning the legitimacy of the activity.
Goffman’s framing theory has been used and adapted by a multitude of social science disci-
plines (Fisher 1997), and has provided useful insights into health policy and systems research
(Koon et al. 2016), including interpreting public health agendas (Driedger and Eyles 2003,
Rothman and Salovey 1997) and patient-professional communication (Coupland et al. 1994).
However, few studies explore service reconﬁguration in light of the construction of multifari-
ous stakeholder frames and consequential outcome for service providers and users (Koon et al.
2016). As such we use the NMS to:
1. Illustrate the dynamic nature of the framing process, in particular, how the NMS policy is
interpreted, framed and enacted by professionals.
2. Understand how NMS interactions and associated contextual and spacio-material embodied
artefacts shape lay-professional, relational and communicative exchanges and how these
processes co-construct stakeholder frames and sense-making of the NMS.
It is recognised that how an activity is framed has signiﬁcant consequences for its outcome.
Importantly then, there is an opportunity to understand how new roles and relational interactions
are constructed and framed according to pre-existing schema, cognitive structures, and values.
The study
The case of the New Medicine Service (NMS)
In line with many other countries, the UK government made signiﬁcant changes in 2005 to
the organisation and delivery of community pharmacy services to improve patient choice,
reduce work pressures on GPs, and to encourage pharmacist involvement in chronic disease
management (Department of Health 2008, Mossialos et al. 2015). The new community phar-
macy contractual framework divided pharmacist work into three categories. ‘Essential services’
(dispensing of medicines, support for self-care, and health promotion etc.), and ‘advanced
service’ (e.g. Medicines Use Review (MUR)) are remunerated at a national level, whereas
‘enhanced services’ (e.g. smoking cessation services) are commissioned locally according to
the area’s needs.
The NMS was based on research that showed that a signiﬁcant proportion of patients start-
ing a long-term medication quickly become non-adherent (Barber et al. 2004). Subsequently, a
theoretically-informed (necessity-concerns framework) intervention was developed which
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involved a pharmacist telephone consultation to follow-up patients prescribed a new medicine
(Elliott et al. 2008). This intervention was found to be cost-effective in reducing non-adherence
and was developed into the NMS, which was introduced as an advanced service in 2011. In
practice, patients are initially invited to participate in the service (engagement) following a pre-
sentation of a prescription for a new medicine. The service comprises two semi-structured
‘conversations’, shaped to explore patients’ understanding and use of their new medicines,
especially to uncover non-adherence, from which individualised educational guidance and
advice can be provided by the pharmacist to promote behaviour change. The consultations are
undertaken (either face-to-face or via telephone) at 7–14 days and a further 14–21 days, after
receiving the new medicine. To encourage pharmacist uptake, pharmacy contractors claim
from the NHS between £20 and £28 per consultation depending on the number of patients
who receive the service in any given month.
The NMS is framed in health policies as a way of helping patients manage newly prescribed
medicines for a long-term condition. Critically, it becomes apparent that by proposing a ‘one
size ﬁts all model’ policymakers consider patients as a homogenous group with normative
claims that they are somehow in need of professional support. On examining the service aims
and intentions, the NMS arguably seeks to promote adherence through the identiﬁcation of
deviant behaviour in relation to patients’ medicine or management of their long-term condition
(Box 1) (PSNC 2011).
Data collection
This paper draws upon the ﬁndings of a qualitative study within a larger appraisal of the NMS
in the English National Health Service (NHS), carried out between Spring 2012 and Autumn
2013. In the ﬁrst instance, a detailed analysis of relevant health policies, training documenta-
tion and research evidence was undertaken to understand the development, implementation
Box 1: NMS service aims and intended outcomes (PSNC 2011).
1. Help patients and carers manage newly prescribed medicines for a Long-term condition
(LTC) and make shared decisions about their LTC
2. Recognise the important and expanding role of pharmacists in optimising the use of
medicines
3. Increase patient adherence to treatment and consequently reduce medicines wastage and
contribute to the NHS Quality, Innovation, Productivity and Prevention (QIPP) agenda
4. Supplement and reinforce information provided by the GP and practice staff to help
patients make informed choices about their care
5. Promote multidisciplinary working with the patient’s GP practice
6. Link the use of newly-prescribed medicines to lifestyle changes or other non-drug inter-
ventions to promote well-being and promote health in people with LTCs
7. Promote and support self-management of LTCs, and increase access to advice to
improve medicines adherence and knowledge of potential side effects
8. Support integration with LTC services from other healthcare providers and provide
appropriate signposting and referral to these services
9. Improve pharmacovigilance
10. Through increased adherence to treatment, reduce medicines-related hospital admissions
and improve quality of life for patients.
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and policy framework of the NMS, especially the discursive expectations, policy aims and
intentions through which the NMS was to be realised.
Following approval by the National Research Ethics Service (NRES), the study next investi-
gated the implementation of the NMS within 23 community pharmacies located in three regions
of the English NHS (London, Midlands, and Yorkshire). Pharmacies were purposively sampled
to reﬂect recognised contextual factors, including pharmacy (ownership) type, geographical area
and social deprivation (see Box 1). Following an ethnographic approach, non-participant obser-
vations were carried out for up to ﬁve days in each site to understand the social organisation of
pharmacy services and day-to-day patient-pharmacist interactions. This provided detailed obser-
vations of how the NMS was organised and delivered as a routine intervention, including obser-
vation of how pharmacists provided information about the service, scheduled and undertook
consultations, and managed patient information during and following the NMS consultation. A
standardised proﬁling template was used to guide observations and developed from similar stud-
ies (Cornford et al. 2012) and from a review of the pharmacy literature.
Twenty patients were recruited to be ‘tracked’ or more closely observed as they experienced
the NMS service. Twenty initial and sixteen follow-up consultations were observed and audio
or video recorded (of the four patients who did not receive a follow up consultation, one
patient withdrew from the study, one received a medicine change and two patients were
referred back to the prescriber). Short (10 minutes) ‘before and after’ interviews were under-
taken with both patient and pharmacist for each tracked NMS consultation to examine how
patients and pharmacists interacted and inﬂuenced one another through the NMS, explore a
priori and posteriori expectations, and how they framed consultations. All observations were
written up in ﬁeld journals and typed up as electronic summaries.
As well as observational data, this study draws on 35 patient interviews exploring different
aspects of pharmacy service and the NMS, and 58 health professional interviews. NMS obser-
vations and the short ‘before and after’ interviews provided the foundation for subsequent
semi-structured qualitative interviews with nineteen patients receiving the NMS (one patient
withdrawal; ten male, nine female). These interviews explored patient reﬂections on the NMS
in light of their previous experiences and interaction with the pharmacist and role of commu-
nity pharmacy services. To facilitate comparison, thirteen patients who initially had agreed to
receive the NMS at the ‘engagement’ stage, but had been randomly allocated to receive
‘usual’ care as part of the wider appraisal were interviewed about their experience of phar-
macy interactions and how they were managing taking their new medicine. Usual care was
the normal supply and advice associated with presentation of a prescription for a new medi-
cine for a long-term condition. In broad terms this was dispensing the medicine(s) and provid-
ing advice at the point of handover to ensure the safe and effective use of the medicine.
Three patients who had declined the invitation to participate in the NMS, were also invited to
an interview (15 minutes) to further understand their reasons for declining to participate in the
service.
Professional experiences and perceptions of the NMS were examined from semi-structured
interviews with 47 community pharmacists and 11 GPs. Pharmacists were recruited through
their involvement in the study’s RCT. GPs whose patients were recruited to the study were
also invited take part and offered an inconvenience allowance of £40. Due to the low numbers
recruited (n = 5), a further six GPs were recruited through the Primary Care Research Network
(PCRN). Full details of sampling and recruitment are reported elsewhere (Elliott et al. 2014).
Analytical approach
Qualitative data analysis started with the initial stages of data collection and proceeded itera-
tively so that emergent ﬁndings were incorporated into subsequent qualitative data collection,
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including the revision of data collection methods. All data were transcribed and imported into
qualitative analysis package NVivo (Version 11, QSR International, Brisbane) for the purpose
of coding through constant comparison, with all authors sharing and comparing interpretations
to clarify the internal consistency of codes and identify conceptual relationships. The coded
data were systematically related back to understanding participant frames, how these were
formed, realised and aligned in relation to other stakeholder groups and policy. We considered
how issues of non-adherence had been framed, the dynamics of how the proposed solution
(NMS) was represented within policy documents, which actors were addressed, and how the
solution (using the community pharmacy) was portrayed. Our analytical approach therefore
sought to understand NMS policy framing, stakeholder interpretation and framing of this pol-
icy, and how these were co-constructed alongside existing norms and expectations. Three
themes that inﬂuenced this process emerged: (i) the spatial-material artefacts that shape and
govern framing and subsequent interpretation of the NMS through this framework; (ii) how
existing discursive culture and practice around medicine-taking inﬂuence NMS frame struc-
tures as well as beliefs; and (iii) NMS interactions and the local situated context in which the
NMS was delivered.
Findings
Pharmacy environment and NMS engagement
Our ﬁrst theme considers the spatial and material artefacts of the community pharmacy as the
primary site for framing the NMS. The most prominent professional activities were for dis-
pensing of prescription medicines and the sale of over-the-counter medicines. Each of the par-
ticipating pharmacies used posters, displays and leaﬂets to promote a range of services, i.e.
inﬂuenza vaccinations, smoking cessation. Not all pharmacies displayed information about the
NMS, and where information was displayed, it was alongside other retail, promotional and
educational materials, allowing limited scope for patients to differentiate new from existing
services. As such, the ‘spatial-material’ embodied artefacts did not clearly covey a new image
or pharmacy function where private, seated consultations about a newly prescribed medicine
could be held.
This interpretation was supported when we observed pharmacists inviting patients to partici-
pate in the NMS. With the exception of one patient (who worked in a pharmacy), none of the
patients who accepted the invitation were actually aware of the NMS or the extended role of
the pharmacist into medicine review. Rather, they appeared to frame pharmacy activities pre-
dominantly as a means to ﬁll prescriptions, obtain advice on minor ailments and to purchase
over-the-counter medicines. The frame itself was based on a ‘pharmacist as supplier’ frame-
work through which these activities were understood. This led to some patients being surprised
when they were offered the NMS as they were unable to reframe the pharmacist invitation
from their well-established or usual frame for which they were accustomed to:
Researcher: Did you expect the service to be offered when you ﬁrst entered the pharmacy?
Patient: No, no I expected just to walk in, get my tablets and then walk out (laugh)
[Patient_NMS_10-1]
Findings from patients who declined the initial offer, further suggested that these patients
did not feel a need to receive the NMS. Patients revealed a lack of awareness of the purpose
of the NMS, a lack of perceived necessity and relevance. With the service being offered with
no existing frame or awareness of ambitions to extend the pharmacists’ role, the offer for an
NMS caught them ‘off-guard’:
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I was taken by surprise when it was offered to me at [name of pharmacy] so I had no
inkling about such a service beforehand. [Patient_Decline_NMS_2]
Interviews with pharmacists also supported the view that patients had poor awareness and
often declined participation. The most common reasons given for patients declining the service
included being short of time, not seeing the relevance, or being confused about what the ser-
vice entailed. Another signiﬁcant barrier was the perceived disconnect between the GP and the
pharmacist, and a perceived ‘duplication’ of work resulting in pharmacists struggling to justify
why patients should engage in the NMS:
A barrier to the service to be honest is mainly when the doctor and nurse or someone is
going to see the patient in the next 2 weeks. Because then patients say well do I need to
come here as well? [Pharmacist_175]
With patient frames aligned strongly with pharmacy’s dispensing function, many pharma-
cists accepted that communicating the aims of the NMS was challenging. As a conse-
quence, they adapted their approach, framing the NMS in ways they thought would
‘convince’ patients to accept the offer. They accomplished this by reassuring patients that
the NMS was not a lengthy activity and by informing them that this was nothing threaten-
ing (i.e. not a policing / reporting activity). To facilitate engagement they offered the NMS
as a phone consultation that was presented as a convenient alternative to a face-to-face
encounter:
Sometimes if you go through everything it kind of just scares people away from it, and they
are ‘Oh I’m not signing up for it’, when all you are doing is calling them up and asking for
a quick chat, which is very informal. [Pharmacist_63_1]
The new medicine
Our second theme unpacks the challenges of engaging patients with the NMS and how
existing patient experiences and beliefs shape understanding. When asked about their new
medicine, most patients reported being content with the level of information received at the
time of prescribing and reported few problems. A minority reported adherence issues.
Rather than returning to the GP, or speaking to the pharmacist, these patients adopted their
own strategies to overcome medicine problems. These ranged from tolerating the medicine
(where the problem was a side-effect), experimenting with the medicine (i.e. changing their
prescribed dose) through to stopping the medicine altogether where they deemed this was
necessary:
When I ﬁrst took it [metformin] I was taking it with cholesterol tablets and for a couple of
days I felt dizzy. So I separated the two tablets . . . I’ve stopped taking the cholesterol to
see if it was the metformin and that dizziness never came back . . . Just for a couple of days
because I wanted to like eradicate which one was making me dizzy. [Patient_No_NMS_120]
Pharmacists and GPs reported that signiﬁcant numbers of patients experienced problems with
medicines. They attributed this to patients fearing side effects, general unwillingness to take
medicines, reports of negative media stories and problems associated with polypharmacy.
Despite the mandate given to support adherence, some pharmacists were sceptical over the
extent to which they could fully uncover or inﬂuence patient medicine-taking behaviour:
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At the end of the day you can talk to them for half an hour, they’ll do exactly what they want
when they get back home . . . nothing you can say will change their mind. [Pharmacist_04-1]
Despite GPs expressing frustration over the lack of time during the medical consultation,
and recognition that medicine adherence was a problem, some GPs were open to the idea
that pharmacists with their expertise in medicines, could help support patient adherence to
medicines
It feels to me as though the pharmacist probably has got more time . . . we can’t do it in 10
minutes, you’re scratching the surface really. So somebody else spending a bit more time
going through it is really important. [GP_07]
However, there was little evidence to suggest the NMS policy had any impact on their prac-
tice or that the NMS policy frame had been effectively constructed as a potential ‘medicine
non-adherence’ solution. One reason for this was that their contact with pharmacists varied but
typically remained minimal, intermittent or ad hoc; the nature of the contact predominantly
being about problems relating to prescription queries, minor errors, supply issues or drug inter-
actions. With the NMS being undertaken in ‘therapeutic silos’ and with a lack of existing
pharmacist-GP interaction, pharmacists reported seeing little difference in their relationships
with GPs. Others have commented on the professional isolation that accompanies community
pharmacy solitary working arrangements (Cooper et al., 2009). As a result, GPs framing of
the NMS was constrained by the lack of information about its aims or personal experience of
how the service beneﬁted their patients:
They [patients] would just say ‘It’s a conversation I’ve had with my pharmacist’. ‘Was that
useful?’ Some will go ‘Yes, I talked it through’ and others will go ‘Well not really, they
just, you know, told me to carry on’. [GP_03]
GPs’ lack of understanding of the NMS, limited collaborative involvement and absence of
clear NMS outcomes inhibited effective framing of the NMS as a means to support patient
adherence. Being outside their circle of inﬂuence, the NMS frame itself was construed as
being a ‘pharmacist pretence’. This led to GPs not valuing the potential beneﬁts, being disin-
terested or at times even being suspicious of the pharmacist intentions. Even pharmacist
acknowledged the NMS potentially encroached on professional boundaries:
I think there’s a lot of suspicion about amongst GPs about what this is about, you know that
we’re trying to do part of their job . . . there needs to be an open and transparent discussion
about what this service is and what it isn’t. [Pharmacist_112]
The consequence of this was that GP referral to the NMS or even feedback when patients had
been referred was limited. Most GPs made little effort to engage patients in the service at the
time of prescribing, with some viewing the NMS as an unnecessary intervention with no clear
beneﬁt and questioning their cost-effectiveness:
I don’t know how much the government are spending on NMS but it must be a phenomenal
amount of money and I’m sure there are better ways of spending that money to do the same
job. [GP_10]
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The NMS interaction
Our ﬁnal theme focuses on the NMS interaction and the impact context has on the framing
process. Analysis of observed NMS consultations revealed these to be typically polite and
friendly encounters with discussions centred on the new medicine. Pharmacists would usually
begin the conversation either by enquiring about the patient’s general wellbeing, e.g. ‘how are
you’ or asking how they were ‘getting on’ with the medicine. In about half of the consulta-
tions the pharmacist iterated the purpose of the consultation framing the activity as a ‘check
on how you are getting on with the new tablets’ or whether they were ‘okay’ with the new
medicine. Pharmacists then predominantly reinforced the prescribers’ instructions, routinely
enquiring about side effects and offering reassurance where these were considered transient or
minor. With few opportunities to set their own agenda, most patients took a passive role
within the consultation:
Pharmacist: Have you been taking it?
Patient: I’ve been taking it, I had a word with the pharmacist, and somebody rang me
from your chemist and I told them I’m getting indigestion when I’m having
this tablet. Now she said it will settle down in a couple of weeks. It’s feeling
a lot better now.
Pharmacist: Oh good excellent, well that’s quite normal, it can, upset your stomach to a
certain extent but it’s usually just a passing thing, it will improve after . . .
Patient: So I used to take it when I’m having breakfast, I’m starting after the breakfast
now.
Pharmacist: Well that’s ﬁne, whichever way suits you. Are you still just taking the one a
day?
Patient: Yeah one a day.
Pharmacist: Have you been taking that every day, have you missed any doses at all?
Patient: No I haven’t missed any days. [Extract_Consultation_130]
The NMS was generally portrayed by patients as a form of governance because of the enquiry
into the new medicine and about how they were coping. However, with the pharmacist invit-
ing and spending time with them, they also interpreted the interaction as an opportunity to talk
with someone with expertise and to ask questions. They perceived the encounter as a caring
and thoughtful gesture. The NMS was therefore framed as being ‘above and beyond’:
It’s the ﬁrst time I’ve been asked to give my opinion, get a chance to talk to somebody.
Because before I never had this opportunity of doing things like that. [Patient_NMS_112]
To sum it up, you actually felt cared for and that’s important isn’t it, that people aren’t just
being dished out medication and that actually there’s a caring service. I would say you felt
somebody is taking an interest in you. [Patient_NMS_102]
When asked to reﬂect on whether the NMS was personally relevant or necessary for them a
range of views emerged. Importantly, patients’ understanding of the NMS was not found to be
dependent upon existing notions or policy intentions of what the NMS was designated to do,
but rather their understand appeared to be framed by what transpired during their interaction
with the pharmacist. For instance, where there were few concerns with medicines or health,
patients did not perceive the NMS to be personally relevant and their poor awareness of what
the NMS could offer led some to ﬁnd it challenging to articulate, or at times even remember,
details of what had been discussed during their consultations:
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Researcher: Do you remember anything of the consultations at all?
Patient: To be quite honest I don’t, no. There was certainly nothing intrusive about it,
there was no problems. [Patient_NMS_169-2]
I think she asked me if, no to be honest I can’t remember and I don’t want to put words
into her mouth that she might not have said. [Patient_NMS_101]
Occasionally patients seized the opportunity to discuss extraneous issues that were unrelated
to the new medicine, such as other ailments or diet. Pharmacist response to, and ﬂexibility to
accommodate, such issues affected patient framing and subsequent interpretation of the NMS,
reinforcing the proposition that what occurred during the consultation signiﬁcantly impacted
on the way the NMS was framed:
I think its [NMS] been very helpful to me because it gave me the opportunity to talk
about the other issues . . . like the water infection I had, and then [name of pharmacist]
made some suggestions about that as well. So on the wider issues I would say it was
invaluable. [Patient_NMS_102]
In contrast, experience and reporting of problematic side-effects allowed patients to con-
struct frames that were amenable with NMS policy intentions. In cases where the patient them-
selves felt it was necessary to stop the medicine, the pharmacist’s intervention provided
legitimacy for this action. The interaction effectively offered patients ‘permission’ to return to
the GP about the matter:
Pharmacist: So I just wanted to see how you’re doing with that one [aspirin].
Patient: The problem is I’m not going to be able to continue taking them . . . Because
they’re giving me a really bad stomach . . . I’ve already had seven days in
hospital with quite a large stomach bleed that needed ﬁve units of blood.
Pharmacist: And when was that?
Patient: That was in 1989 . . . as soon as I started taking the aspirin. I started to get
sore quite quickly and then it lasted for about 16 hours before my stomach
seemed to settle down and then I took the next one again with my tea and it
got even worse . . . So I don’t know really what my options are.
Pharmacist: No that’s ﬁne. What we are going to do we are going to refer you back to the
doctors . . . I can send a letter back to the doctors saying what side effects you
are experiencing and I would advise you not to take the tablets any more
. . . [Extract_Consultation_169-1]
The uncertainty that patients felt taking the decision to stop medicines was made easier when
supported by the pharmacist:
It was well worthwhile having a second opinion on whether I’d either done the right thing
. . . I think even if the pharmacist had said yeah you’ll have to persevere with it, I don’t
think I could have done, but that isn’t what he said, so no it was a valuable second opinion
to me. [Patient_NMS_169-1]
The discourse during these NMS interactions appeared to have developed the patient’s
frame of the NMS and extended the frame of the pharmacists’ role. This was towards a con-
cordant frame where patient-pharmacist decision-making was being shared. This frame enable
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patients to more fully recognise the pharmacists’ expertise and the support they could poten-
tially provide. There was evidence to suggest changes to patients’ behaviour had occurred:
I do ask more advice of the pharmacy now than I used to . . . I went in the other day about
some tablets and they said take this . . . Before I wouldn’t have done that, I’d have just gone
in the shop, took a box off the shelf, paid for it and walked out.
[Patient_NMS_112]
The shift in how the patient-pharmacist interaction enabled and shaped the framed the
NMS was clearest when comparisons were made between those who had been randomised
to receive the NMS and those who did not. For those who had not received the NMS,
patient frames remained static, being ﬁxed on the supply and retail functions of pharmacy.
When hearing about the NMS for the ﬁrst time, their pre-conceived frames constrained
their understanding resulting in them raising questions about whether pharmacists could
spare time to undertake such activities and even whether the pharmacist had the jurisdic-
tion to intervene:
It would be well worth it. Whether they’ve [pharmacists] got time to do it I don’t know. It
is time consuming after all. [Patient_No_NMS_114]
If my GP has prescribed something, my GP is the one who needs to know what’s
going off with it, not the pharmacist . . . The pharmacist issues it. If I get an ice cream
from an ice cream van, I don’t go to the corner shop and say I don’t like this ice
cream. [Patient_No_NMS_103 3]
Interestingly where a patient had reported a medicine problem, such as a side-effect, their
frames appeared more malleable allowing the possibility for them to understand how pharma-
cists’ greater involvement, even when they had not experienced the NMS, could be helpful,
suggesting patients were capable of re-framing and better contextualising the extended role if
they appreciated, or personally experienced, the context in which the service could be valued:
He’d [pharmacist] would have the opportunity to say to me, ‘I think you should see a
doctor’, or maybe he could say ‘well don’t worry about that because that’s normal for
that sort of drug, but if it’s really worrying you I advise you to go see a doctor’.
[Patient_No_NMS_167]
Pharmacist interviews provided insights into the way they re-framed, interpreted and then
cascaded the aims of the service. This was found to be not always aligned with the NMS pol-
icy aims and intentions. Overall, the framing of the NMS acted as a means to improve their
relationship and sought to govern medicine use. With increasing realisation that patients expe-
rienced problems with medicines, the NMS was interpreted as a support encounter. The NMS
was often perceived as a way to ‘check’ how patients were coping with taking the new medi-
cine, to offer help managing side effects, answering questions and providing information.
However, NMS encounters in practice often did not identify signiﬁcant problems with the
patients’ medicines or matters of adherence:
I would say the majority of NMS that I have done, people are taking medicine regularly
. . . about 15% of patients have either not been taking the medicine or having problems
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with the device . . . And we were able to, for the majority of them, turn them around
with advice to give them the opportunity to make an informed choice about taking the
medicine or not. [Pharmacist_113]
Although it was clear community pharmacies combined retail business alongside profes-
sional clinical services, there was little evidence that the sale of medicines created role strain.
However, pharmacists’ interpretation of the NMS policy frame was inﬂuenced by organisa-
tional views that the NMS was an income stream. Several commented that the NMS had come
about to offset income loss associated with recent reductions in government dispensing bud-
gets. For employee pharmacists, their interpretation of the NMS policy frame and subsequent
motivation to engage with the service appeared to be more inﬂuenced by organisational pres-
sure rather than an aspiration to improve patient medicine use. Several pharmacists felt uneasy
where their professional responsibilities towards the patient’s welfare conﬂicted with commer-
cial interests. The NMS was being framed to patients in one way but some had a different
views about it ‘backstage’. This resulted in them expressing disquiet about their own motiva-
tions for carrying out the service:
I think, if only this patient knows that the reason why you are ringing at that time is
because you need to make sure you get paid. [Pharamcist_102]
If the target is not there then you can choose people you think that are really going to bene-
ﬁt . . . so when the money is involved, we have to recruit everybody. [Pharmacist_169]
Discussion
Through investigating the introduction of the NMS within the English NHS, this work extends
understanding of the lay-professional framing process, how it is inﬂuenced by spatial-material
artefacts, discourse and situated within professional structures and practices. Despite criticisms
of framing theory, including methodological imperfections (Manning 1992), lack of deﬁni-
tional consensus (Scheff 2006) and divergent views on how framing inﬂuences thinking
(Vliegenthart and Van Zoonen 2011), frame analysis has allowed for an exploration of how
the NMS policy frame becomes manifest in pharmacists day-to-day delivery of the NMS, and
how perception and understanding is generated and organised within everyday reality.
The NMS policy originated from evidence suggesting that pharmacists could extend their
professional role in supporting patients’ medicines adherence (Barber et al. 2004). It was evi-
dent from our data that both patient and professional accounts suggest patients experience
problems with medicines indicating a common shared or ‘aligned’ frame. However, framing of
the potential solution (in our case the NMS) was in practice found be more complex and varie-
gated being dependent on the perceived need or value, the context of who and where this sup-
port was offered. The NMS policy frame in many instances remained unrealised and
professional inconsistencies developed particularly when patients’ frames were found to be
misaligned resulting in low engagement and even resistance to the service. One proposed rea-
son for this misalignment was that pharmacists are expected to realise the aims of the NMS
within an established and embedded role that is located within conventional and largely unad-
justed institutional practices and discourse. The impact of these well-established frames was
that even patients who received the NMS appeared to have frames that were ‘misaligned’
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having constructed these based on strips of activity of what actually had occurred during the
NMS rather than what should have occurred. This may explain ﬁndings from other studies
suggesting patients’ motivation to engage in similar pharmacy medicine review services are
driven by a tendency to politeness and cooperation rather than self-interest or the prospect of
personal beneﬁt (Latif et al. 2013). In extreme cases, patient frames appeared to have col-
lapsed where there was ambiguity or poor prior understanding of the NMS. Furthermore, the
absence of materials issues during the NMS hindered opportunities for frames to be con-
structed and sense-making to happen.
The NMS policy frame appears to have been successfully constructed when patients, in
Goffman’s terms, were able to form new ‘keyed’ frames that extended or replaced their exist-
ing primary frame of reference. The crucial difference in these cases was that patient keying
originated mainly from personal experience of a particular issue related to a new medicine for
which they perceived support could be offered. The new interactions and routines offered
through the NMS could more easily be embedded by patients to enable an alternative story to
be construed that helped them form and replace existing frames (Jarratt and Mahafﬁe 2009).
In effect, overt realisation of the NMS policy aims and intentions became manifest through
enactment or in what Goffman (1974) would portray as it being necessary for the individual to
understand the actual outcome or end-product of activities of others during the interaction. Our
ﬁndings support the idea that interventions should be targeted to people that require them and
that a service can only be inﬂuential to the extent that they are relevant or applicable to the
users’ pre-existing predispositions and perceptions (Nisbet and Scheufele 2009). Signiﬁcantly,
this study challenges policy and professional assumptions that reorganisation of services can
be proposed without signiﬁcant promotion, support, and review of current patient care path-
ways. Consideration of the existing division of labour and patient and professional frames are
needed to allow any new service to be more readily accepted and adopted.
At a societal level, lessons can be drawn from social movement theorists with particular
attention to the process by which ‘ordinary people make sense of public issues’ often with
regards to challenging established orthodoxies (Benford 1994: 1103). Mass movements are said
to be successful when the frames projected align with the frames of actors to produce what is
known as frame resonance between parties. ‘Collective action frames’ are important for estab-
lishing both a common understanding of a social issue and the route through which the issue
should be challenged. This frame alignment is key to the process of a group transitioning from
one frame to another. Relating this to the NMS, if similar policy-lay-professional frame reso-
nance is to occur, effective vignettes or other novel strategies are needed to educate and inform
patients about how and when the NMS could be valuable, what happens during the process and
what outcomes can be expected. With current NMS and other pharmacy medicine review pro-
motional materials being found wanting (Van Den Berg and Donyai 2010), a review of promo-
tional and public campaigns are needed in order to generate emotional engagement among
segments of the public who may be indifferent, medically under-served or unacquainted with
newer pharmacy services (Nisbet and Scheufele 2009, Latif et al. 2016, 2018).
Our study indicates that greater service traction may be possible if frame alignment (mainly
with prescribers) is achieved. In order to improve awareness of the potential value to doctors
and to patients, greater integration of the NMS with other health services is needed. For exam-
ple, in Australia physicians are responsible for the referrals of patients to the HMR service
(Pharmaceutical Society of Australia 2011). Moreover, responsibility also rests with policy-
makers and employers to ensure organisational targets and target-linked remuneration for
undertaking the NMS do not lead to perverse incentives, as found in other healthcare settings
(Mears 2014). Our study suggests that some pharmacists might have interpreted the NMS pri-
marily as a means of securing income, over and above a health promotion intervention.
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Although these are not necessarily mutually exclusive, the motivation of pharmacists could
have implications for their consequent framing of the NMS with patients, including what
might be interpreted as ‘fabricated’ frames, where underlying ﬁnancial motives are overlaid
with a health promotion frame.
In conclusion, our study offers an explanatory view of the NMS framing process that has
important lessons beyond medicine management policy to potentially any reconﬁgured service.
Our case illustrates framing as being dynamic, variegated, complementary or conﬂicting, and
how this plurality and fragility had consequences for patient engagement and sense-making. In
light of these ﬁndings, policy and professional assumptions that suggest patients can be cate-
gorised and treated as a homogenous group requires reconsideration and service innovation so
that a more personalised care approach can be introduced. Recent work indicates the NMS
increases patient adherence to a new medicine by about 10% when compared with normal
practice and increases health gain at reduced overall cost (Elliott et al. 2017). This paper offers
recommendations so service improvements can be made to ensure the service realises its full
potential. Whereas the ﬁndings are embedded within the analysis of agency, the analysis did
not seek to include the ‘interaction of the powerful’ (Giddens 1987: 134) or circumstances in
which ‘power’ is exercised as this has been explored elsewhere (Waring et al. 2016). Further
work may be needed to understand how professional power and inﬂuence affect framing and
the consequences for patient care.
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